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Abstract
Background: Viral load monitoring (VLM) to identify individuals failing antiretroviral therapy (ART) is not widely
available in resource-limited settings. We compared the genotypic resistance patterns between clients with VLM
versus immunological monitoring (IM).
Methods: Between 2004–2008, 559 ART naïve clients were enrolled in a prospective cohort, initiated on ART, and
monitored with viral load (VL) and CD4+ cell counts every 6 months (VLM group). From February 2008 through
June 2009, 998 clients on ART for 36–40 months (corresponding to the follow-up time of the VLM group) at the
same clinic and monitored with CD4+ cell counts every 6 months were recruited into a cross sectional study (IM
group). Samples from VLM clients at 12, 24 and 36 months and IM clients at 36–40 months with VL > 2000 copies/
ml underwent genotypic drug resistance testing.
Results: Baseline characteristics were similar. Virologic failure (VL > 400 copies/ml) at 12, 24 and 36 months in the
VLM group were 12%, 6% and 8% respectively, and in the IM group 10% at 36–40 months. Samples from 39 VLM
and 70 IM clients were genotyped. 23/39 (59%) clients in the VLM group (at 12, 24 or 36 months) compared to 63/
70 (90%) in the IM group, (P < 0.0001) had at least 1 non-nucleoside reverse transcriptase mutation. 19/39 (49%) of
VLM clients had an M184V mutation compared to 61/70 (87%) in the IM group (P < 0.0001). Only 2/39 (5%) of VLM
clients developed thymidine analogue mutations compared to 34/70 (49%) of IM clients (P < 0.0001).
Conclusions: Routine VL monitoring reduced the rate of accumulated genotypic resistance to commonly used ART
in Uganda.
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Background
Antiretroviral treatment (ART) programs have scaled up
to reach over 5.2 million HIV-infected individuals in
need of life-saving treatment in low and middle income
countries by the end of 2009 [1]. Most of these indivi-
duals live in settings where laboratory monitoring is lim-
ited and treatment failure is determined using either
clinical or immunological criteria. Concern has been
raised regarding the performance of clinical and
immunologic treatment failure criteria to correctly iden-
tify individuals with virologic failure [2-7]. Prolonged vir-
ologic failure may result in accumulation of resistance
mutations to commonly used first-line ART as observed
in Malawi and elsewhere [8,9]. This could compromise
second-line treatment outcomes and also increase the
risk of transmitted HIV drug resistance.
Failure to achieve or maintain virologic suppression
for prolonged periods of time may lead to the sequential
development of thymidine analogue mutations (TAMs)
in clients taking nucleoside reverse transcriptase inhibi-
tors (NRTIs) such as zidovudine (ZDV) or stavudine
(d4T) as part of their ART regimens [9-12]. The accu-
mulation of 3 or 4 TAMs confers drug resistance across
* Correspondence: sjreynolds@niaid.nih.gov
1Division of Intramural Research, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, MD, USA
2Johns Hopkins University School of Medicine, Baltimore, MD, USA
Full list of author information is available at the end of the article
© 2012 Reynolds et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Reynolds et al. BMC Infectious Diseases 2012, 12:381
http://www.biomedcentral.com/1471-2334/12/381
the NRTI class of antiretroviral (ARV) drugs and has
implications for future ART regimens, particularly in
resource-limited settings (RLS) where second-line ART
options are limited. ZDV, tenofovir (TDF) and to a lesser
extent d4T are currently used as the nucleoside back-
bone of the first-line and some second-line regimens in
sub-Saharan Africa and other RLS areas.
The objective of our study was to compare genotypic
resistance patterns (with particular attention to TAMs)
among a group of clients on first-line ART at an urban
clinic in Kampala, Uganda, who were monitored both
clinically, immunologically and virologically as part of a
research cohort study to a similar group of clients




The Infectious Diseases Institute (IDI) of Makerere Uni-
versity College of Health Sciences (Kampala, Uganda) is a
center of excellence in the delivery of HIV clinical care,
research and training, with over 10,000 active clients
registered including over 6,500 receiving ART. Eligibility
criteria for ART at the time of this study (February 2008
through June 2009) were CD4 < =200 cells/ul or WHO
stage IV disease; first-line regimens included stavudine or
zidovudine plus lamivudine and nevirapine or efavirenz.
Study population
The IDI routine care clinic (immunological monitoring (IM)
group)
Clients attending the routine care clinic who become
eligible for ART are offered adherence counseling prior
to ART and also during follow-up if deemed necessary
by clinicians. Clients are seen monthly for follow-up
assessments, drug refills and monitored through pro-
spective CD4+ cell counts every 6 months. Treatment
failure was assessed according to the WHO immuno-
logic or clinical criteria for treatment failure [13]. A
more detailed description of this population is presented
elsewhere [14].
The IDI research cohort (viral load monitoring (VLM) group)
A nested research cohort within the routine care clinic
was established in 2004, with a consecutive prospective
enrollment of 559 ART-naïve clients who initiated ART
from April 2004 through April 2005; clients enrolled
in this cohort are monitored through both CD4+ counts
and viral load measurement (Amplicor HIV-1 Monitor
PCR Test, version 1.5; Roche Diagnostic, GmbH Mo-
lecular Systems, Pleasanton, CA with a detection limit of
400 copies/ml), every 6 months; plasma is also stored for
future investigations. A more detailed description of the
study procedures and data collection has been presented
elsewhere [15]. In brief, ART-eligible adults (> = 18 years
of age) were enrolled in the study if they fulfilled the
following eligibility criteria: 1) confirmed HIV type 1
infection; 2) regular attendance at clinic visit, based on
at least 2 clinic visits within the previous 6 months; 3)
stable residence within a 20-km radius of Kampala; 4)
willingness to be followed at the Infectious Diseases In-
stitute for at least 2 years; and 5) eligibility for ART
according to the World Health Organization (WHO)
2003 and Uganda Ministry of Health (ie, a CD4+ cell
count < = 200 cells/ul or WHO stage IV), and 6) pro-
vision of written informed consent. Clients were seen
every three months by the study clinicians and monthly
for routine clinical visits and drug refills. Clients were
considered for switch to second line ART if they had
two HIV VL > 1000 copies/ml on two consecutive
measurements.
Study design
From February 2008 through June 2009, a cross sec-
tional study was conducted in the IDI routine care clinic
population recruiting a convenience sample of clients
who were on first-line ART regimens for 36–40 months
(corresponding to the length of follow-up time reached
by IDI research cohort clients). Clients still on first-line
ART were consecutively recruited during their monthly
follow-up visits. After providing written informed con-
sent, blood was drawn for HIV viral load (VL), CD4+
cell count and plasma was stored for genotyping. Ge-
notyping was done on all clients found to have an HIV
VL > 2,000 copies/ml (corresponding to the sensitivity
threshold of the assay). Results of the viral load and
genotyping test were made available to the physicians
for clinic management of their clients.
In the research cohort clients, those alive and in care
at 12 months were considered eligible for this analysis.
We included any research cohort client having a HIV
VL of >2000 copies/ml while still on first-line at months
12, 24 or 36 of follow-up; however, clients who had a
detectable VL above 2,000 copies/ml up to month 12
but subsequently (months 24 or beyond) became viro-
logically suppressed without regimen change were not
included in the genotyping analysis as these were
considered to have early adherence problems rather than
drug resistance [16]. All clients in both groups were
followed-up regardless of treatment change. Genotyping
was done retrospectively on stored plasma samples.
Genotypic mutation patterns of the first occurrence of a
viral load >2,000 copies/ml in the research cohort clients
and the mutation patterns observed among in the rou-
tine clinic population at 36–40 months were compared.
All genotypes reported on VLM clients were obtained
prior to switch to second-line treatment.
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Statistical methods
Baseline characteristics for both monitoring groups were
compared using the Fisher exact test for categorical
variables (gender, WHO staging, ART regimen) and
Mann–Whitney U test for continuous variables (age,
CD4+ count, hemoglobin, body mass index). We used
the Mann–Whitney U test to compare median CD4+
count increase at follow-up. We used the t-test for
proportions to assess differences in mutation rates
across monitoring groups. All P values are two-sided.
All analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC) or Stata version 11.1 (StataCorp,
College Station, TX).
Laboratory procedures
Plasma was separated within 2 hours from blood draw and
stored immediately at −80°C. HIV-1 RNA was tested with
the Roche Amplicor MONITOR v1.5 assay (Roche Mo-
lecular Systems, Nutley, New Jersey, USA). HIV-1 RNA
was extracted from plasma samples using a Qiagen RNA
extraction method (Qiagen Inc., Chatsworth, California,
USA). Polymerase gene-specific primers were used for
reverse transcriptase, followed by 750 base pair pol gene
encompassing amino acids 1–242 of reverse transcriptase.
The PCR products was then purified using the QIAquick
PCR purification kit (Qiagen, Valencia, California, USA)
and sequenced using Beckman Coulter sequencing kit
(Beckman Coulter Inc., Fullerton, CA). The obtained
sequences were then edited using BioEdit sequence edi-
tor version 7.0.4. The cleaned sequences were then
uploaded into the Stanford University HIV Drug resis-
tance database to obtain the drug resistance profile.
Genotyping assays were performed at the Joint Clinical
Research Center laboratory in Kampala. For genotype
analysis, mutations were generally categorized according
to the International AIDS Society-USA recommenda-
tions [17].
Ethics
All study participants from the IDI routine care clinic
provided written informed consent, while the partici-
pants from the IDI research cohort had already provided
consent at study enrollment for future use of stored
plasma. The study was approved by the National AIDS
Research Council Ethics Board, the Uganda National
Council for Science and Technology, and the National
Institute of Allergy and Infectious Diseases Intramural
Institutional Review Board.
Genbank accession numbers: KC008609 to KC008711.
Results
Four hundred forty one of the 559 research cohort cli-
ents (VLM group) were alive and in care at 12 months
and included in this analysis. Nine hundred ninety-eight
clients on ART for 36–40 months were recruited from
the routine clinic population (IM group). Table 1
displays the demographic characteristics for the VLM
and IM clients. Characteristics of patients in the VLM
and IM group at ART initiation were similar; particularly
median baseline CD4+ cell count was 102 (IQR 31–170)
cells/μl for VLM clients and 86 (29–154) for IM clients.
The median CD4+ change from baseline to 36 months
was 227 (146–336) for VLM clients and 251 (148–377)
for IM clients; virologic failure rates (VL > 400 copies/
ml) at 12, 24 and 36 months were 12%, 6% and 8%
respectively for VLM clients and 10% at 36–40 months
for IM clients.
Samples from 39 VLM and 70 IM clients were suc-
cessfully amplified and genotyped (Figure 1a & 1b).
Some VLM clients had more than one time point sent
for genotyping resulting in a total of 45 unique geno-
types for this group; among clients with >1 genotype,
the first available result was used to compare VLM and
IM clients as this was considered to be the time point
when a switch of therapy would be considered. Among
VLM clients, rates of resistance were relatively stable
over 36 months follow-up (Table 2). The most common
class of resistance was to the non-nucleoside reverse
transcriptase inhibitors (NNRTIs) ranging from 50%
(8/16) at 12 months, 69% (9/13) at 24 months and 60%
(6/10) at 36 months. Resistance to lamivudine was
present among 50% (8/16) at 12 months, 62% (8/13) at
24 months and 40% (4/10) at 36 months. Very few VLM
clients developed any resistance to the nucleoside re-
verse transcriptase inhibitors (NRTIs) apart from the
M184V mutation.
Comparing the 39 first genotypes from VLM clients to
the 70 IM clients, 23/39 (59%) of VLM clients as
opposed to 63/70 (90%) in the IM group had at least 1
NNRTI mutation (p < 0.0001) (Table 3). Nineteen out of
thirty-nine (49%) of VLM clients had an M184V muta-
tion compared to 61/70 (87%) of IM clients (P < 0.0001).
Only 2/39 (5%) of the VLM clients developed TAMS
whereas 34/70 (49%) of IM clients developed TAMS
(p < 0.001) with 7/70 (10%) developing > = 3 TAMS
(Figure 2).
We also compared the 10 VLM clients with genotype
results at 36 months to the 70 IM clients at 36 months,
6/10 (60%) of VLM clients as opposed to 63/70 (90%)
in the IM group had at least 1 NNRTI mutation
(p = 0.1034). Four out of ten (40%) of VLM clients had
an M184V mutation compared to 61/70 (87%) of IM cli-
ents (P = 0.0185). None of the VLM clients developed
TAMS whereas 34/70 (49%) of IM clients developed
TAMS (p < 0.0001).
A total of 26 clients in the VLM cohort were switched
from first to second-line ART in the first 36 months of
follow-up, while all patients in the IM group reached
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36 months on first-line ART without clinicians suspect-
ing treatment failure. The median number of VL mea-
surements before switch was 4 and median VL prior to
switch was 21,773 (IQR 5,104-210,918).
Discussion
Although the proportion of clients failing ART at
36 months was comparable between those monitored
with VL and compared to those monitored with CD4+
cell counts only, the proportion of the clients with
multiple resistance mutations especially TAMS was
significantly higher in the IM clients. This is the first
observational study directly comparing genotypic resist-
ance profiles to commonly used antiretroviral drugs
between individuals monitored with virologic compared
to immunologic monitoring alone. Several studies have
documented the lack of sensitivity of immunologic and
clinical criteria to identify individuals failing ART raising
concern regarding the potential for increased genotypic
resistance to ART, which could result [3-6]. High rates
of genotypic resistance to first-line ART have been
observed in Malawi, Uganda and India where clinical
and immunologic criteria have been used to identify
treatment failure [8,11,18]. In addition, poor outcomes
following first-line regimen failure have been documen-
ted in Malawi possibly due to advanced immuno-
suppression and ART resistance [19]. The results of our
study add more evidence to the growing body of litera-
ture supporting some degree of viral load monitoring
in RLS.
The participants enrolled in the IM cohort in this
study were clients who had not been identified as having
any evidence of treatment failure by clinicians. In con-
trast to most studies looking at resistance among clients
in RLS, this was not a selected group of individuals fail-
ing by immunologic or clinical criteria and would have
been left on first-line ART if VL testing was not done as
part of this study. The significant degree of resistance
observed in this group raises concern about the need for
periodic VL monitoring in settings where none is
currently available in routine care. A moderate propor-
tion of clients had multiple TAMS possibly resulting in
compromised efficacy of commonly used second-line
ART regimens available in RLS.
Our study has limitations; it is not a randomized clin-
ical trial and therefore unmeasured bias between the
VLM and IM groups remains a possibility. Because the
IM group was cross-sectional, we have no data on lost
to follow-up or number of deaths before study enroll-
ment; however, we would expect clients lost to care to
do as poorly or worse with respect to rates of virologic
failure. Clients enrolled in the VLM group followed
certain inclusion criteria including living within 20 km
of the clinic and willingness to attend to visit schedules
which could also select for a more adherent population
compared to the IM group. The use of stored specimens
resulted in some amplification failures among the VLM
group, which could possibly affect our overall results. Fi-
nally, we have no information on duration of virologic
failure among the IM group to allow us to control for
Table 1 Baseline Characteristics
Characteristic IM (n = 998) VLM (n = 441) P-value
Age (IQR yrs) 36.2 (31.5 – 41.3) 35 (30 – 41) 0.002
Gender 0.667
Female 680 (68%) 306 (69%)
Male 318 (32%) 135 (31%)
Baseline CD4 (IQR cells/μl) 86 (29–154) 101.5 (30.5-170) 0.330
WHO Stage (n = 996) <0.0001
WHO Stage I 18 (2%) 2 (1%)
WHO Stage II 233 (23%) 49 (11%)
WHO Stage III 478 (48%) 257 (58%)
WHO Stage IV 267 (27%) 133 (30%)
Hb (IQR) 11.3 (10.0 – 12.7) 11.7 (10.6 – 13.0) 0.001
BMI (IQR kg/m2) 20.2 (18.2 – 22.5) 20.2 (18.3 – 22.6) 0.917
ART Regimen 0.726
d4T/3TC/NVP 721 (72%) 325 (74%)
d4T/3TC/EFV 3 (0.5%) 0
ZDV/3TC/NVP 2 (0.5%) 0
ZDV/3TC/EFV 272 (27%) 116 (26%)
IM: Immunologically monitored; VLM: Virologically monitored; IQR: Interquartile Range; Hb: Hemoglobin; BMI: Body mass index; ART: antiretroviral therapy;
d4T: stavudine; 3TC: lamivudine; ZDV: zidovudine; NVP: nevirapine; EFV: efavirenz.
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duration of failure which could influence the mutation
patterns observed.
Despite the limitations mentioned pertaining to study
design, baseline characteristics, treatment setting and
study staff were all similar. Virologic and immunologic
characteristics at 36 months of follow-up were also simi-
lar between the two groups. . We believe the reduced
rate of resistance, particularly to NRTIs, observed among
VLM clients is explained by the frequent VL monitoring
and ability to detect and allow caregivers to discuss ad-
herence and possibly switch to second-line regimens
prior to the development of extensive drug resistance.
Our results support ongoing efforts to improve
adherence counseling strategies as treatment programs
continue to scale up access. Our study was not designed
to look at longer term mortality benefits between our
VLM and IM clients, however, a recent multi-country
study conducted in Malawi, Zambia and South Africa
suggested that the lower rate of mortality observed
among South African ART programs could be explained
in part by the presence of VL monitoring and timely
switch to second-line regimens [20]. As ART programs
continue to scale up in RLS and funding constraints
limit the choices of monitoring options, the debate over
how best to monitor clients will continue. Some con-
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b
Figure 1 a. Enrollment and accrual: Immunologically monitored clients. b. Virologically monitored clients. VL: Viral Load.
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monitoring over immunologic or clinical monitoring
[21,22]. Retention and adherence in these clinical trials
is clearly higher than in the operational context of this
study and may not be generalizable to operational
contexts. Cost benefit studies have also suggested that
allocating resources to earlier initiation of ART could
provide more benefit than routine VL monitoring [23].
We feel it is equally important to evaluate monitoring
strategies in a real world setting outside the support of a
clinical trial where participants receive maximum adher-
ence support and therefore risks of virologic failure are
minimized. It is also important not to consider only an
all or none approach to VL monitoring and consider
new strategies using periodic VL monitoring at fixed time
points during follow-up as a recent study in Thailand
found cost-effective among pediatric clients [24].
Table 2 Resistance over time for virologically monitored
(VLM) clients
Month 12 Month 24 Month 36
(N = 16) (N = 13) (N = 10)
NRTI mutations
Any TAMs 2 (12) 0 (0) 0 (0)
1 TAMs 1 (6) 0 (0) 0 (0)
2 TAMs 1 (6) 0 (0) 0 (0)
3+ TAMs 0 (0) 0 (0) 0 (0)
41L 0 (0) 0 (0) 0 (0)
65R 1 (6) 1 (8) 1 (10)
67N 1 (6) 0 (0) 0 (0)
70R 1 (6) 0 (0) 0 (0)
184I/V 7 (44) 8 (62) 4 (40)
210W 0 (0) 0 (0) 0 (0)
215F/Y 1 (6) 0 (0) 0 (0)
NNRTI mutations
Any NNRTI mutation 8 (50) 9 (69) 6 (60)
90I 0 (0) 0 (0) 0 (0)
98G 0 (0) 0 (0) 0 (0)
101E 1 (6) 0 (0) 0 (0)
103N 3 (19) 3 (23) 3 (30)
108I 0 (0) 0 (0) 2 (20)
138A/G 0 (0) 0 (0) 0 (0)
179D 0 (0) 0 (0) 0 (0)
181C/I 0 (0) 4 (31) 2 (20)
188L/H 0 (0) 1 (8) 0 (0)
190A/S 3 (19) 2 (15) 1 (10)
225H 0 (0) 0 (0) 0 (0)
230L 0 (0) 0 (0) 0 (0)
Bold: major mutations.
VLM: Virologically monitored; NRTI: nucleoside reverse transcriptase inhibitor;
TAMs: thymidine analogue mutations; NNRTI: non-nucleoside reverse
transcriptase inhibitor.
Table 3 Resistance comparing IM versus VLM patients
IM VLM
(N = 70) (N = 39)
NRTI mutations
Any TAMs 34 (49) 2 (5)
1 TAMs 13 (19) 1 (3)
2 TAMs 14 (20) 1 (3)
3+ TAMs 7 (10) 0 (0)
41L 8 (11) 0 (0)
65R 1 (1) 3 (8)
67 N 11 (16) 1 (3)
70R 13 (19) 1 (3)
184I/V 61 (87) 19 (49)
210W 1 (1) 0 (0)
215F/Y 25 (36) 1 (3)
NNRTI mutations
Any NNRTI mutation 63 (90) 23 (59)
90I 5 (7) 0 (0)
98 G 5 (7) 0 (0)
101E 8 (11) 1 (3)
103N 23 (33) 10 (26)
108I 10 (14) 2 (5)
138A/G 3 (4) 0 (0)
179D 1 (1) 0 (0)
181C/I 22 (31) 6 (15)
188L/H 3 (4) 1 (3)
190A/S 13 (19) 6 (15)
225H 6 (9) 0 (0)
230L 1 (1) 0 (0)
Bold: major mutations.
IM: Immunologically monitored; VLM: Virologically monitored; NRTI: nucleoside
reverse transcriptase inhibitor; TAMS: thymidine analogue mutations; NNRTI:
non-nucleoside reverse transcriptase inhibitor.
Figure 2 Resistance by monitoring strategy. VLM: Viral load
monitoring; IM: Immunological monitoring; NNRTI: Non-nucleoside
reverse transcriptase inhibitor; TAMS: Thymidine analogue mutations.
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Conclusions
Access to viral load monitoring remains a priority for
countries continuing to scale up ART in order to limit
the emergence of drug resistance. Further studies are
warranted to evaluate novel monitoring strategies that
minimize resistance, maximize positive clinical out-
comes, recognizing cost constraints faced by programs
challenged by ever increasing numbers needing HIV
treatment.
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